Yuk Ting

6.6k total citations · 1 hit paper
65 papers, 1.1k citations indexed

About

Yuk Ting is a scholar working on Oncology, Hepatology and Surgery. According to data from OpenAlex, Yuk Ting has authored 65 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 25 papers in Hepatology and 18 papers in Surgery. Recurrent topics in Yuk Ting's work include Hepatocellular Carcinoma Treatment and Prognosis (25 papers), Pancreatic and Hepatic Oncology Research (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Yuk Ting is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (25 papers), Pancreatic and Hepatic Oncology Research (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Yuk Ting collaborates with scholars based in United Kingdom, France and Taiwan. Yuk Ting's co-authors include Daniel H. Palmer, Paul J. Ross, Tim Meyer, Philip J. Johnson, Richard Hubner, Peter L. Collins, T.R. Jeffry Evans, David Cunningham, John Primrose and Nigel Hacking and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Yuk Ting

62 papers receiving 1.1k citations

Hit Papers

Sorafenib in combination with transarterial chemoembolisa... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
    2017 331 citations Tim Meyer, Yuk Ting et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuk Ting United Kingdom 16 583 426 331 294 251 65 1.1k
Xinyu Bi China 17 400 0.7× 480 1.1× 316 1.0× 216 0.7× 289 1.2× 100 1.2k
Li‐Jian Liang China 17 535 0.9× 474 1.1× 250 0.8× 292 1.0× 133 0.5× 33 986
Wen‐Feng Gong China 14 800 1.4× 324 0.8× 277 0.8× 436 1.5× 156 0.6× 29 1.1k
Andrea Gardini Italy 19 665 1.1× 440 1.0× 538 1.6× 386 1.3× 283 1.1× 40 1.3k
Jie Mei China 18 525 0.9× 263 0.6× 211 0.6× 212 0.7× 151 0.6× 51 898
Anna Kan China 16 361 0.6× 275 0.6× 157 0.5× 168 0.6× 173 0.7× 38 927
Hirokazu Chishina Japan 18 900 1.5× 225 0.5× 199 0.6× 378 1.3× 195 0.8× 44 1.1k
Bin‐Yan Zhong China 17 660 1.1× 221 0.5× 246 0.7× 256 0.9× 265 1.1× 74 1.0k
Jun Sakata Japan 19 415 0.7× 473 1.1× 463 1.4× 242 0.8× 269 1.1× 65 991
Keun Soo Ahn South Korea 20 499 0.9× 481 1.1× 660 2.0× 268 0.9× 326 1.3× 66 1.2k

Countries citing papers authored by Yuk Ting

Since Specialization
Citations

This map shows the geographic impact of Yuk Ting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuk Ting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuk Ting more than expected).

Fields of papers citing papers by Yuk Ting

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuk Ting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuk Ting. The network helps show where Yuk Ting may publish in the future.

Co-authorship network of co-authors of Yuk Ting

This figure shows the co-authorship network connecting the top 25 collaborators of Yuk Ting. A scholar is included among the top collaborators of Yuk Ting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuk Ting. Yuk Ting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zakeri, Nekisa, Rachel M. Brown, Owen Cain, et al.. (2024). SIMAP500: A novel risk score to identify recipients at higher risk of hepatocellular carcinoma recurrence following liver transplantation. World Journal of Transplantation. 14(3). 95849–95849. 1 indexed citations
2.
Kamarajah, Sivesh K., Alessandro Parente, Timothy M. Pawlik, et al.. (2023). Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers. 15(12). 3166–3166. 7 indexed citations
3.
Ting, Yuk, et al.. (2022). 28 Blood culture collection practices in NICU; A national survey. Paediatrics & Child Health. 27(Supplement_3). e14–e14. 2 indexed citations
4.
Virtakoivu, Reetta, Jenna H. Rannikko, Miro Viitala, et al.. (2021). Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clinical Cancer Research. 27(15). 4205–4220. 41 indexed citations
5.
Zakeri, Nekisa, Yuk Ting, Joanne O’Rourke, et al.. (2021). Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit. British Journal of Cancer. 125(10). 1350–1355. 28 indexed citations
6.
Bono, Petri, Panu Jaakkola, Shishir Shetty, et al.. (2020). 1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer. Annals of Oncology. 31. S706–S707. 1 indexed citations
7.
Kalisvaart, Marit, Francesca Marcon, Rupaly Pandé, et al.. (2020). Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study. HPB. 22(9). 1240–1249. 24 indexed citations
8.
Palmer, Daniel H., Juan W. Valle, Yuk Ting, et al.. (2020). TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial. British Journal of Cancer. 122(7). 971–977. 49 indexed citations
9.
Dasari, B., Sivesh K. Kamarajah, James Hodson, et al.. (2019). Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver. HPB. 22(3). 383–390. 8 indexed citations
10.
Palmer, Daniel H., Yuk Ting, Markus Peck‐Radosavljevic, et al.. (2018). A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. British Journal of Cancer. 118(9). 1162–1168. 26 indexed citations
11.
Javed, Muhammad A., Georg Beyer, Alessio Vinci, et al.. (2018). Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology. 19(1). 97–104. 33 indexed citations
12.
13.
Edeline, Julien, J.F. Blanc, Boris Campillo‐Gimenez, et al.. (2017). Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score. European Journal of Cancer. 86. 135–142. 21 indexed citations
14.
15.
Palmer, Daniel H., Syed A. Hussain, Anna Jo Bodurtha Smith, et al.. (2013). Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. British Journal of Cancer. 109(4). 888–890. 17 indexed citations
16.
Ting, Yuk & Daniel H. Palmer. (2012). Impact of restricting access to high-cost medications for hepatocellular carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research. 12(4). 465–473. 6 indexed citations
17.
Ting, Yuk, Stuart I. Collins, Lawrence S. Young, Paul G. Murray, & C B J Woodman. (2011). Smoking initiation is followed by the early acquisition of epigenetic change in cervical epithelium: a longitudinal study. British Journal of Cancer. 104(9). 1500–1504. 31 indexed citations
18.
Ting, Yuk, Michael Cullen, & Syed A. Hussain. (2011). Biology of Germ Cell Tumors. Hematology/Oncology Clinics of North America. 25(3). 457–471. 4 indexed citations
19.
Geh, J I & Yuk Ting. (2011). Evolution of systemic therapy for metastatic colorectal cancerdoi. Colorectal Disease. 13(8). 852–854. 1 indexed citations
20.
Hussain, Syed A., Yuk Ting, D. Palmer, Paul Hutton, & Michael Cullen. (2008). Biology of testicular germ cell tumors. Expert Review of Anticancer Therapy. 8(10). 1659–1673. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xinyu Bi Breakdown of academic impact, for papers by Li‐Jian Liang Breakdown of academic impact, for papers by Wen‐Feng Gong Breakdown of academic impact, for papers by Andrea Gardini Breakdown of academic impact, for papers by Jie Mei Breakdown of academic impact, for papers by Anna Kan Breakdown of academic impact, for papers by Hirokazu Chishina Breakdown of academic impact, for papers by Bin‐Yan Zhong Breakdown of academic impact, for papers by Jun Sakata Breakdown of academic impact, for papers by Keun Soo Ahn
Rankless by CCL
2026